BioSpring launches Bioscovy for PrEP in global market

Date:2022-09-20 Views: 31 Times

September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth. 

Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV.

Bioscovy for PrEP is not for everyone:

  • It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness has not been studied.
  • You must be HIV-negative before and while taking Bioscovy for PrEP.

We wish this product every success in the global market and hope that it will create an image for the company and increase exports.

Bioscovy-taf-em-1
Bioscovy-taf-em-2

About Pharmaceutical Third Party Manufacturing

Pharma Third party manufacturing/contract manufacturing provide easy solution for manufacturing of own brands.

Third party or contract manufacturing is referred to outsourcing of products or to get manufactured one’s brand names from others manufacturing unit out. In current time it is very popular concept among marketing companies. Even companies having their own manufacturing units are gotten manufactured their products from outside. Multinational companies are also gotten manufactured their products at loan license or third-party basis.

About BioSpring.Ltd

Founded in 2022 at the Vientiane Saiseta Comprehensive Development Zone in Laos, BioSpring is the country's fastest growing generic drug manufacturing company and the country's first pharmaceutical company targeting the international market, serving Asia, Africa, Europe and Latin America Americas and many other countries and regions.

Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.

Source

BioSpring launches Bioscovy for PrEP in global market - BioSpring.Ltd

Link

Poster

Top